Industry News
Biotechnology Industry News
Bristol Myers Squibb’s…
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival among multiple myeloma patients.
Xenon Pharmaceuticals’…
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients.
Shanghai-based Tenacia…
Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for a Rapport Therapeutics asset focused on focal onset seizures and primary generalized tonic-clonic seizures, securing rights to develop and commercialize the candidate in China.
AbbVie has unveiled the first data…
AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in certain patients.
Pfizer is ramping up plans for…
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs.
Regeneron’s Chinese partner…
Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.
A phase 3 trial of Roche’s…
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug candidate that hit the mark in adjuvant and second-line settings.
Italian pharma Alfasigma is…
Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve in a couple of weeks.
After a tumultuous tenure marked…
After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post as the FDA’s top regulator of vaccines and cell and gene therapies at the end
San Francisco venture capital firm…
San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence.
The FDA is ending a roughly…
The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings, convening its first session of 2026 to scrutinize a pair of oncology applications from AstraZeneca.
The planned closure of Bio Palette…
The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to the technology under
After 27 years with Bavarian…
After 27 years with Bavarian Nordic, including 12 as CEO, Paul Chaplin is stepping down from the helm at the Danish vaccine maker and moving back to Australia. Under his leadership, Bavarian Nordic blossomed from
Zealand Pharma’s Roche-partnered…
Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at 42 weeks in a phase 2 obesity trial.
In a strikingly blunt briefing, a…
In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy for Huntington’s disease.
Merck KGaA is no longer pursuing…
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.
Flagship Pioneering-backed Alltrna…
Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people.
The back-and-forth between the FDA…
The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now denying the biotech’s claims about a sham trial request for the rare Huntington’s disease.
Cardiovascular biotech Tenaya…
Cardiovascular biotech Tenaya Therapeutics has signed a research collaboration agreement with RNAi specialist Alnylam Pharmaceuticals in a deal that includes a $10 million upfront payment and much more in potential milestone payments for Tenaya if
The FDA has put a partial clinical…
The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop-start advance of the program. Guggenheim Securities analysts blamed the hold on an “understaffed